Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1181 to 1190 of 1849 total matches.

Tramadol/Celecoxib (Seglentis) for Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022  (Issue 1648)
in additive effects. Use of a monoamine oxidase (MAO) inhibitor with or within 14 days of tramadol ...
The FDA has approved Seglentis (Esteve/Kowa), an oral combination of tramadol hydrochloride, a weak opioid agonist and weak serotonin and norepinephrine reuptake inhibitor (SNRI), and celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID), for use in adults with acute pain that is severe enough to require an opioid and for which alternative treatment options are inadequate.
Med Lett Drugs Ther. 2022 Apr 18;64(1648):58-60 |  Show IntroductionHide Introduction

Rosiglitazone/Glimepiride (Avandaryl) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
mg once 29.10 Amaryl (Aventis) (max 8 mg) 38.70 1. Cost of 30 days’ treatment (8 mg/d ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
Med Lett Drugs Ther. 2006 Mar 13;48(1230):22-4 |  Show IntroductionHide Introduction

Telavancin (Vibativ) for Gram-Positive Skin Infections

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010  (Issue 1329)
4.50 Bactrim DS (Mutual) 7.41 1. Cost of 1 day’s treatment of a 70 kg patient according to AWP ...
Telavancin (Vibativ - Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria in adults.
Med Lett Drugs Ther. 2010 Jan 11;52(1329):1-2 |  Show IntroductionHide Introduction

Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025  (Issue 1724)
mg/60 mg/150 mg once/day in patients ...
The FDA has approved Alyftrek (Vertex), an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily treatment of cystic fibrosis (CF) in patients ≥6 years old who have at least one F508del mutation or another responsive mutation in the CFTR gene. This is the first approval for vanzacaftor and for deutivacaftor, a deuterated form of ivacaftor. Trikafta, a twice-daily oral fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor, is FDA-approved for the same indication...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):41-3   doi:10.58347/tml.2025.1724a |  Show IntroductionHide Introduction

In Brief: Lowering the Dose of Lunesta

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014  (Issue 1444)
occur. 1. FDA Drug Safety Communication. FDA warns of next-day impairment with sleep aid Lunesta ...
The FDA has required the manufacturer of eszopiclone (Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours.1 Eszopiclone’s half-life is longer than that of any other drug in its class, which includes zolpidem (Ambien, and generics) and zaleplon (Sonata, and generics).All benzodiazepine receptor agonists may impair performance the next morning,...
Med Lett Drugs Ther. 2014 Jun 9;56(1444):48 |  Show IntroductionHide Introduction

In Brief: Expanded Access to Mifepristone

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics ...
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):31   doi:10.58347/tml.2023.1670c |  Show IntroductionHide Introduction

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
the previous 5 days, or baloxavir marboxil within the previous 17 days. Use of influenza antiviral drugs ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

In Brief: Safety of Quinine

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2010  (Issue 1350)
was about 13 days. Most patients with thrombocytopenia recovered when quinine was stopped.1 In addition ...
Qualaquin, the only formulation of quinine sulfate available in the US, is approved only for treatment of uncomplicated malaria, but most prescriptions for its use are written for treatment or prevention of nocturnal leg cramps. The FDA recently issued a warning about its safety.Between April 2005 and October 2008, 38 cases of serious or life-threatening adverse effects of quinine were reported to the FDA. Twenty-one of these patients had thrombocytopenia and required hospitalization. Two deaths were reported: one from hemolysis and the other from thrombotic thrombocytopenic purpura (TTP)....
Med Lett Drugs Ther. 2010 Nov 1;52(1350):88 |  Show IntroductionHide Introduction

Varenicline (Chantix) for Tobacco Dependence

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006  (Issue 1241)
) in about 4 hours. 3 With daily dosing, plasma concentrations reach a steady state after 4 days ...
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this article.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):66-8 |  Show IntroductionHide Introduction

Soft Contact Lenses

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990  (Issue 823)
(approved for one- to 30-day use), overnight use of daily-wear lenses (approved for use only while awake ...
Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have emerged.
Med Lett Drugs Ther. 1990 Jul 27;32(823):69-70 |  Show IntroductionHide Introduction